I don't think the area for adjunctive therapy is done, just yet. Most of the studies were done early on, some which showed promise, needing more trials, while other studies did not show much benefit, but there are new drugs now, target therapies, that are being used in trials, and for local control, maintenance, chemoprevention, secondary tumor prevention in HNSCC like with with Erbitux, Tarceva (erotinib), celexobib (Cox-2), and combinations like Erotinib and Cox-2, which shows to be better combined, than either alone, in chemoprevention with premalignant lesions in head and neck cancer. There is a phase I and II trial with Everolimus as adjunct therapy after definitive therapy with no sign of cancer.

Primary chemotherapy in HNSCC falls into three main treatments catergories: (1)Neoadjunct chemotherapy, designed to reduce tuumor burden prior to definitive locaal control; (2) concomitant chemotherapy, and(3) adjunct chemotherpy, designed to maintain patients (or to prevent recurrence) after difinitive local contol.